uniQure N.V. $QURE is Artia Global Partners LP’s 9th Largest Position

Artia Global Partners LP raised its position in shares of uniQure N.V. (NASDAQ:QURE) by 55.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,023,539 shares of the biotechnology company’s stock after purchasing an additional 364,700 shares during the quarter. uniQure accounts for about 3.4% of Artia Global Partners LP’s holdings, making the stock its 9th biggest holding. Artia Global Partners LP’s holdings in uniQure were worth $24,493,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in QURE. Vanguard Group Inc. lifted its position in shares of uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after purchasing an additional 152,417 shares during the period. Aberdeen Group plc lifted its position in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after purchasing an additional 738,897 shares during the period. Quinn Opportunity Partners LLC purchased a new stake in shares of uniQure in the 3rd quarter worth about $6,281,000. Farallon Capital Management LLC lifted its position in shares of uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after purchasing an additional 551,000 shares during the period. Finally, Boone Capital Management LLC purchased a new stake in shares of uniQure in the 3rd quarter worth about $8,599,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Activity at uniQure

In related news, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the transaction, the insider owned 169,669 shares of the company’s stock, valued at $4,251,905.14. This trade represents a 20.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeannette Potts sold 5,237 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.67, for a total value of $144,907.79. Following the transaction, the insider directly owned 133,246 shares of the company’s stock, valued at approximately $3,686,916.82. This trade represents a 3.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 101,054 shares of company stock worth $2,655,791 over the last quarter. 4.65% of the stock is currently owned by company insiders.

uniQure Trading Up 78.4%

Shares of NASDAQ QURE opened at $48.16 on Thursday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The stock has a market cap of $3.04 billion, a P/E ratio of -13.84 and a beta of 0.98. The firm has a 50-day moving average of $23.55 and a 200 day moving average of $21.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. As a group, sell-side analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on QURE shares. HC Wainwright dropped their target price on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wolfe Research started coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Finally, Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research report on Tuesday, May 5th. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $47.17.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure said it plans to submit a BLA for AMT-130 in Huntington’s disease after the FDA indicated the company’s three-year data may support accelerated approval, a major regulatory win that could speed the drug toward market. Article Title
• Positive Sentiment: Analysts turned more constructive after the FDA update, with Cantor Fitzgerald upgrading QURE to overweight and lifting its price target, reinforcing the market’s bullish reaction. Article Title
• Positive Sentiment: Options activity also picked up, with traders buying unusually large volumes of call options, suggesting strong speculative demand tied to the FDA catalyst. Article Title

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.